La semaglutide appartiene a una classe di farmaci noti come agonisti del recettore GLP-1 (glucagon-like peptide-1)
Individual Results Vary: Weight loss outcomes are influenced by adherence to the program, the prescribed dose, personal metabolic rate, diet, physical activity, and other lifestyle variables
This post is intended for health professionals and does not replace personalised clinical advice
Average weight loss in a 2022 study, for example, was 5.9% at the three month mark and 10.9% at six months
This has also been studied in women with PCOS, who also reported increased natural pregnancy rates and improved cycle regularity
(Source: ScienceDaily, 2025) Semaglutide Delivers Major Weight Loss in Adults Over 65 A 2026 study presented at the European Association for the Study of Obesity found that older adults (65+) taking once-weekly semaglutide experienced substantial weight loss and improvements in multiple health measures with results similar to those seen in the broader STEP trial population